Viatris stock slides 24% as analysts say sale of biosimilars to Indian partner removes key growth driver - MarketWatch

‘Total consideration of $3.335B is simply too good to walk away from in our view,’ says Raymond James

Viatris Inc. said Monday it has agreed to combine its biosimilars portfolio with privately held Indian company Biocon Biologics Ltd. for up to $3.335 billion, as part of a broader overhaul of its bus… [+3160 chars]

full article...